A case of severe euglycemic ketoacidosis arising during dapagliflozin intake


DOI: https://dx.doi.org/10.18565/therapy.2024.6.129-136

Katushkina Yu.A., Tatarintseva Z.G., Kosmacheva E.D.

1) Professor S.V. Ochapovsky Research Institute – Regional Clinical Hospital No. 1 of the Ministry of Healthcare of Krasnodar territory, Krasnodar; 2) Kuban State Medical University of the Ministry of Healthcare of Russia, Krasnodar
Abstract. Patients with type 2 diabetes mellitus (T2 DM) are highly susceptible to heart failure developing, which is known as a leading cause of morbidity and mortality in this population. In this regard, inhibitors of sodium-glucose cotransporter type 2 (SGLT2), which have not only a positive effect on metabolic control, but also proven cardio- and nephroprotection, are of particular relevance. In rare cases, under certain unfavorable conditions, an increase of ketone bodies concentration in the serum during SGLT2 inhibitors treatment takes place, leading to euglycemic ketoacidosis. Article describes a clinical case of male patient with T2 DM who, after bariatric surgery for morbid obesity, developed severe euglycemic metabolic ketoacidosis associated with dapagliflozin intake. Timely identification and adequate therapy made it possible in shortest time compensate that condition and discharge the patient from the hospital.
Keywords: ketoacidosis, sodium-glucose cotransporter type 2 inhibitor, dapagliflozin, type 2 diabetes mellitus, heart failure
Read entire article

Literature

1. Braunwald E. The war against heart failure: The Lancet lecture. Lancet. 2015; 385(9970): 812–24.


https://doi.org/10.1016/S0140-6736(14)61889-4. PMID: 25467564.


2. American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes – 2019. Diabetes Care. 2019; 42(Suppl 1): S103–S123.


https://doi.org/10.2337/dc19-S010. PMID: 30559236.


3. Gallo L.A., Wright E.M., Vallon V. Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences. Diab Vasc Dis Res. 2015; 12(2): 78–89.


https://doi.org/10.1177/1479164114561992. PMID: 25616707. PMCID: PMC5886707.


4. Zinman B., Wanner C., Lachin J.M. et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117–28.


https://doi.org/10.1056/NEJMoa1504720. PMID: 26378978.


5. Neal B., Perkovic V., Mahaffey K.W.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377(7): 644–57.


https://doi.org/10.1056/NEJMoa1611925. PMID: 28605608.


6. Perkovic V., Jardine M.J., Neal B. et al.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380(24): 2295–306.


https://doi.org/10.1056/NEJMoa1811744. PMID: 30990260


7. Wiviott S.D., Raz I., Bonaca M.P. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347–57.


https://doi.org/10.1056/NEJMoa1812389. PMID: 30415602.


8. Zelniker T.A., Wiviott S.D., Raz I. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393(10166): 31–39.


https://doi.org/10.1016/S0140-6736(18)32590-X. PMID: 30424892.


9. Паюдис А.Н., Ефремова О.А., Камышникова Л.А. с соавт. Влияние ингибиторов SGLT2 на течение хронической сердечной недостаточности у больных сахарным диабетом 2-го типа. Клиницист. 2022; 16(2): 10–16. (Payudis A.N., Efremova O.A., Kamyshnikova L.A. et al. Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus. Klinisist = The Clinician. 2022; 16(2): 10–16 (In Russ.)).


https://doi.org/10.17650/1818-8338-2022-16-2-K656. EDN: OAUOAH.


10. Verma S., Juni P., Mazer C.D. Pump, pipes, and filter: Do SGLT2 inhibitors cover it all? Lancet. 2019; 393(10166): 3–5.


https://doi.org/10.1016/S0140-6736(18)32824-1. PMID: 30424891.


11. Cotter D.G., Schugar R.C., Crawford P.A. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013; 304(8): H1060–76.


https://doi.org/10.1152/ajpheart.00646.2012. PMID: 23396451. PMCID: PMC3625904.


12. Puchalska P., Crawford P.A. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 2017; 25(2): 262–84.


https://doi.org/10.1016/j.cmet.2016.12.022. PMID: 28178565. PMCID: PMC5313038.


13. Mudaliar S., Polidori D., Zambrowicz B., Henry R.R. Sodium-glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport: From bench to bedside. Diabetes Care. 2015; 38(12): 2344–53.


https://doi.org/10.2337/dc15-0642. PMID: 26604280.


14. Yabe D., Iwasaki M., Kuwata H. et al. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study. Diabetes Obes Metab. 2017; 19(5): 739–43.


https://doi.org/10.1111/dom.12848. PMID: 27990776. PMCID: PMC5412941.


15. Aubert G., Martin O.J., Horton J.L. et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016; 133(8): 698–705.


https://doi.org/10.1161/CIRCULATIONAHA.115.017355. PMID: 26819376. PMCID: PMC4766035.


16. Munro J.F., Campbell I.W., McCuish A.C., Duncan L.J.P. Euglycemic diabetic ketoacidosis. Br Med J. 1973; 2(5866): 578–80.


https://doi.org/10.1136/bmj.2.5866.578. PMID: 4197425. PMCID: PMC1592207.


17. Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015. URL: https://wayback.archive-it.org/7993/20170112031553/http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm (date of access – 04.06.2024).


18. Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2015. URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about (date of access – 04.06.2024).


19. Fralick M., Schneeweiss S., Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017; 376(23): 2300–2.


https://doi.org/10.1056/NEJMc1701990. PMID: 28591538.


20. Meyer E.J., Gabb G., Jesudason D. SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: A South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care. 2018; 41(4): E47–E49.


https://doi.org/10.2337/dc17-1721. PMID: 29440112.


21. Стронгин Л.Г., Малышева Е.С., Сергеева Т.В. с соавт. Случай эугликемического диабетического кетоацидоза, ассоциированного с применением ингибиторов натрий-глюкозного котранспортера 2-го типа. Focus Эндокринология. 2020; 1(1): 60–65. (Strongin L.G., Malysheva E.S., Sergeeva T.V. et al. The case of euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitors application. Focus Endokrinologiya = Focus Endocrinology. 2020; 1(1): 60–65 (In Russ.)).


https://doi.org/10.47407/ef2020.1.1.0008. EDN: XIUWDQ.


22. Fayfman M., Pasquel F.J., Umpierrez G.E. Management of hyperglycemic crises: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Med Clin North Am. 2017; 101(3): 587–606.


https://doi.org/10.1016/j.mcna.2016.12.011. PMID: 28372715. PMCID: PMC6535398.


23. Milder D.A., Milder T.Y., Kam P.C.A. Sodium-glucose co-transporter type-2 inhibitors: Pharmacology and peri-operative considerations. Anaesthesia. 2018; 73(8): 1008–18.


https://doi.org/10.1111/anae.14251. PMID: 29529345.


24. Perry R.J., Rabin-Court A., Song J.D. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun. 2019; 10(1): 548.


https://doi.org/10.1038/s41467-019-08466-w. PMID: 30710078. PMCID: PMC6358621.


25. Donnan K., Segar L. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol. 2019; 846: 23–29.


https://doi.org/10.1016/j.ejphar.2019.01.002. PMID: 30639796. PMCID: PMC6364569.


26. Chan M.J., Weng C.H., Hsu C.W. et al. Dapagliflozin associated ketoacidosis: A must know fact for nephrologists. Nephrology (Carlton). 2018; 23(2): 192.


https://doi.org/10.1111/nep.13039. PMID: 29346842.


27. Perkovic V., Neal B. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380(24): 2295–306.


https://doi.org/10.1056/NEJMoa1811744. PMID: 30990260.


28. Handelsman Y., Henry R.R., Bloomgarden Z.T. American Association of Clinical Endocrinologists and American College of Endo­crinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016; 22(6): 753–62.


https://doi.org/10.4158/EP161292.PS. PMID: 27082665.


29. Pujara S., Ioachimescu A. Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin. J Invest Med High Impact Case Rep. 2017; 5(2): 2324709617710040.


https://doi.org/10.1177/2324709617710040. PMID: 28589154. PMCID: PMC5446101.


About the Autors

Yulia A. Katushkina, MD, endocrinologist at the Department of endocrinology, Research Institute – Regional Clinical Hospital No. 1 named after professor S.V. Ochapovsky, assistant at the Department of therapy No. 1 of the Faculty of advanced training and professional retraining of specialists, Kuban State Medical University of the Ministry of Healthcare of Russia. Address: 350901, Krasnodar, 140 Rossiyskaya St.
E-mail: ukadoc@gmail.com
ORCID: https://orcid.org/0009-0009-7334-9928
Zoya G. Tatarintseva, MD, PhD (Medicine), head of the Department of cardiology, Research Institute – Regional Clinical Hospital No. 1 named after professor S.V. Ochapovsky. Address: 350901, Krasnodar, 140 Rossiyskaya St.
E-mail: z.tatarintseva@list.ru
ORCID: https://orcid.org/0000-0002-3868-8061
Elena D. Kosmacheva, MD, Dr. Sci. (Medicine), professor, head of the Department of therapy No. 1 of the Faculty of advanced training and professional retraining of specialists, Kuban State Medical University of the Ministry of Healthcare of Russia, deputy chief physician for medical affairs, Research Institute – Regional Clinical Hospital No. 1 named after professor S.V. Ochapovsky. Address: 350086, Krasnodar, 167 Pervogo Maya St.
E-mail: kosmachova_h@mail.ru
ORCID: https://orcid.org/0000-0001-5690-2482


Similar Articles

Back to Content

Бионика Медиа